300 million health records: Regeneron puts up to $200M into TriNetX

NodeGuardian · 2026-04-03T00:32:48+00:00

Regeneron Pharmaceuticals is partnering with TriNetX in a $200 million investment to access a vast electronic health record network. This collaboration will enhance Regeneron's database for AI-driven health solutions, accelerating drug discovery while ensuring compliance with privacy laws.

NodeGuardian

2026-04-03 00:32:48

Abstract generation in progress

Regeneron Pharmaceuticals (NASDAQ: REGN) has announced a strategic collaboration with TriNetX, involving an investment of up to $200 million, to access TriNetX’s de-identified electronic health record (EHR) network, which contains approximately 300 million patient records globally, including 170 million in the U.S. This partnership will enable Regeneron to expand its Genetics Center’s (RGC) EHR-linked database and enhance its AI training algorithms for digital health solutions. The collaboration aims to accelerate drug discovery, development, and the creation of innovative digital health tools, all while adhering to strict privacy laws like HIPAA and GDPR.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.